Literature DB >> 29248337

Clinical efficacy of the novel thiazolidinedione lobeglitazone in patients with type 2 diabetes.

J-Y Lee1, Y Cho1, M Lee1, Y-H Lee2, B-W Lee2, E S Kang2, B-S Cha3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29248337     DOI： 10.1016/j.diabet.2017.11.005

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN： 1262-3636            Impact factor:   6.041


× No keyword cloud information.
  2 in total

1.  Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis.

Authors:  Jaehyun Bae; Gyuri Kim; Yong-Ho Lee; Byung-Wan Lee; Eun Seok Kang; Bong-Soo Cha
Journal:  Diabetes Ther       Date:  2018-12-01       Impact factor: 2.945

Review 2.  Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus.

Authors:  Jaehyun Bae; Taegyun Park; Hyeyoung Kim; Minyoung Lee; Bong-Soo Cha
Journal:  Diabetes Metab J       Date:  2021-04-19       Impact factor: 5.376
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.